Drug Profile

NXL 001

Alternative Names: NXL-001

Latest Information Update: 05 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuExcell Therapeutics
Class Antidementias; Gene therapies; Neuroprotectants
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Alzheimer's disease; Stroke

Most Recent Events

05 Aug 2025 NXL 001 is still in preclinical phase for Stroke in USA (Parenteral) (NeuExcell Therapeutics pipeline, August 2025)
05 Feb 2024 Preclinical trials in Alzheimer's disease in USA, prior to January 2024 (Parenteral) (NeuExcell Therapeutics pipeline, January 2024)
13 Oct 2022 NeuExcell Therapeutics plans to file an IND application for Stroke program in Q4 2023 (NeuExcell Therapeutics pipeline, October 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com